Emerging Business Models in the Pharmaceutical Industries ...

More documents

Recommendations

Info

Introduction GlaxoSmithKline (GSK) and its subsidiaries and associated undertakings constitute a global health care group engaged in the creation, discovery, development, manufacture and marketing of pharmaceuticals (prescription pharmaceuticals and vaccines), and consumer health care products (over-the-counter medicines, oral care and nutritional healthcare). GSK has operations in 38 countries with the principal research and development facilities located in the United Kingdom, the United States, Japan, Italy and Belgium. Products are sold in over 130 countries, and the major markets are the United States, Japan, France, Germany, the United Kingdom and Italy. GlaxoSmithKline plc - Revenues The group is able to continue to deliver pharmaceutical turnover growth, despite generic competition, primarily due to a broad product portfolio of fast growing, high value products. 50 40 30 20 10 GSK Revenue by Segment 15% (in percentage) 85% Pharmaceutical Consumer Healthcare GSK's Five Year Financial Performance (in billion US$) 1999 2000 2001 2002 2003 Source: Company’s Annual Reports Source: Company’s Annual Reports Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 60 34% 32% 30% 28% 26% 24% Revenues Operating Profits Profit Margins
20 15 10 5 0 GSK Revenues by Geography (billion US$) USA Europe Other Countries Source: Company’s Annual Reports GlaxoSmithKline plc Strategic Direction GSK follows the network research model, collaborating with research companies for rapid development of new drugs. Since the group was formed in December 2000, it has signed 36 major external collaborations, 24 for products in clinical development and a further 12 for products at the preclinical stage. The company’s overall pipeline has 148 projects and 90 new clinical entities. GSK have entered into a research collaboration, option and license agreement in the area of systems biology for drug discovery and development in metabolic diseases. GSK R&D has formed ADI (alternative drug discovery initiative) partnerships with biotechnology companies and other pharmaceutical companies to explore different approaches to drug discovery. 2001 2002 2003 The company has been focusing on oncology and cardiovascular sectors. However with Paxil and Wellbutrin not performing very well, questions are being raised about GSK's blockbuster model. Current collaborative ADI partnerships are: • Cytokinetics Inc. (oncology: mitotic kinesin inhibitors) • Shionogi & Co., (HIV and neurology programmes: potential broad based discovery collaboration in antimicrobials, oncology, metabolic and neurology) • Tanabe Seiyaku Co. Ltd. (broad based: neurology, gastro-intestinal, urology, diabetes, respiratory) • Exelixis Inc. (oncology, inflammation) • Theravance Inc. (asthma) • Ranbaxy Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 61
Page 1 and 2:
Emerging Business Models in the Pha
Page 3 and 4:
Table of Contents Introduction…
Page 5 and 6:
Acronyms Big Pharmas The top global
Page 7 and 8:
Introduction Pharma Industry Overvi
Page 9 and 10: Market Segmentation Getting Blurred
Page 11 and 12: Growth in the Pharma Market The pha
Page 13 and 14: Factors Restraining Pharma Market R
Page 16 and 17: Geographic Overview Introduction No
Page 18 and 19: Trends in the Pharma Industry Short
Page 20 and 21: Long Term Strategies - Forward Inte
Page 22 and 23: Long Term Strategies - Targeted Tre
Page 24 and 25: Long Term Strategies - Biotech and
Page 26 and 27: Long Term Strategies - Biotech and
Page 28 and 29: Overview of the Network Model The n
Page 30 and 31: Outsourcing The network approach al
Page 32 and 33: Many of BMS's key drugs are from ot
Page 34 and 35: Growth in Semi Block Busters Even i
Page 36 and 37: Short Term Strategies - Pre- and Po
Page 38 and 39: Short Term Strategies Against Paral
Page 40 and 41: There are two main types of M&Q act
Page 42 and 43: The Revenue Model The market dynami
Page 44 and 45: Short Term and Mid Term Strategies
Page 46 and 47: Top 10 Pharma Companies - Major Mar
Page 48 and 49: Benchmarking - Top 20 Drugs by Sale
Page 50 and 51: Benchmarking by Percentage Growth i
Page 52 and 53: Benchmarking by Geographic Revenue
Page 54 and 55: Rank 1 2 3 4 5 JnJ GSK Company Pfiz
Page 56 and 57: Altace® Biaxin® Zofran® Brands A
Page 58 and 59: Introduction Pfizer is the world's
Page 62 and 63: Introduction Merck & Co. develops,
Page 64 and 65: Introduction Aventis’ core busine
Page 66 and 67: Introduction Bristol-Myers Squibb C
Page 68 and 69: Strategic Direction The company aim
Page 70 and 71: Strategic Direction JnJ has been fo
Page 72 and 73: 15% Percentage Revenues by Segment
Page 74 and 75: 12 10 8 6 4 2 0 The Americas Revenu
Page 76 and 77: 20 15 10 5 0 Novartis revenues by S
Page 78 and 79: Strategic Direction Eli Lilly focus
Page 80 and 81: New Revenue Models New revenue mode
Page 82: Contact Us For more information on
show all

Emerging Business Models in the Pharmaceutical Industries ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?